Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Diabetes

Journal Scan / Research · December 04, 2024

Effects of SGLT2 Inhibitor Use on the Incidence of New-Onset Diabetes Among Patients With Cardiovascular or Kidney Disease

European Heart Journal

 

Additional Info

Disclosure statements are available on the authors' profiles:

European Heart Journal
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease
Eur Heart J 2024 Nov 21;[EPub Ahead of Print], JW Ostrominski, MC Højbjerg Lassen, BL Claggett, ZM Miao, SE Inzucchi, KF Docherty, AS Desai, PS Jhund, L Køber, P Ponikowski, MS Sabatine, CSP Lam, FA Martinez, RA de Boer, AF Hernandez, SJ Shah, M Petersson, AM Langkilde, JJV McMurray, SD Solomon, M Vaduganathan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading